.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,592,466

« Back to Dashboard

Details for Patent: 8,592,466

Title:Methods for treating conditions caused by higher-than-normal dopaminergic activity in basal ganglia
Abstract: Treatment of humans suffering from conditions caused by higher-than-normal dopaminergic activity in basal ganglia includes administering the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiaz- olidinyl}carbonylmethyl)ureido]phenyl}propionic acid and its physiological acceptable salts.
Inventor(s): Elkashef; Ahmed (Dunn Loring, VA)
Assignee: Neuropill, Inc. (Dunn Loring, VA)
Filing Date:Jul 18, 2012
Application Number:13/552,182
Claims:1. A method for treating a disease in a human characterized by higher-than-normal dopaminergic activity in basal ganglia comprising: administration of a compound of formula (I) ##STR00002## or a physiologically acceptable salt thereof to the human, the compound being administered in an amount effective to treat at least one symptom of the disease; wherein the at least one symptom of the disease comprises at least one of hallucinations, delusions, anhedonia, poverty of speech, and cognitive impairment.

2. The method of claim 1, wherein the compound of formula (I) or the physiologically acceptable salt thereof is administered orally.

3. The method of claim 1, wherein a capsule containing the compound of formula (I) is orally administered.

4. The method of claim 1, wherein a tablet containing the compound of formula (I) is orally administered.

5. The method of claim 2, wherein an aqueous solution containing the compound of formula (I) is orally administered.

6. The method of claim 2, wherein an aqueous suspension containing the compound of formula (I) is orally administered.

7. The method of claim 1, wherein the physiologically acceptable salt thereof is alkali metal, alkaline earth or ammonium salt.

8. The method of claim 1, wherein the effective amount is 200 to 1600 mg of the compound of formula (I).

9. The method of claim 1, wherein the compound of formula (I) or the physiologically acceptable salt thereof is administered topically.

10. The method of claim 1, wherein a transdermal patch containing the compound of formula (I) is topically administered.

11. The method of claim 1, wherein the disease characterized by a higher-than-normal level of dopaminergic activity in the basal ganglia comprises a disease characterized by a higher-than-normal level of dopaminergic activity in the human's striatum.

12. The method of claim 1, wherein the compound of formula (I) is administered in combination with an atypical antipsychotic drug.

13. A pharmaceutical composition in unit dosage form for treating a disease characterized by a higher-than-normal level of dopaminergic activity in a human's basal ganglia comprising: per dosage unit 800 to 1600 mg of a physiologically acceptable salt of a compound of formula (I) ##STR00003## with a pharmaceutically acceptable carrier in solid or liquid form.

14. A method for decreasing dopamine levels in basal ganglia comprising: administrating a compound of formula (I) ##STR00004## or physiologically acceptable salt thereof to a human diagnosed as having a disease characterized by a higher-than-normal level of dopaminergic activity in the basal ganglia, the compound being administered in an amount effective to decrease dopamine levels in basal ganglia of the human.

15. The method of claim 14, wherein the compound of formula (I) or the physiologically acceptable salt thereof is administered orally.

16. The method of claim 15, wherein a capsule containing the compound of formula (I) is orally administered.

17. The method of claim 15, wherein a tablet containing the compound of formula (I) is orally administered.

18. The method of claim 15, wherein an aqueous solution containing the compound of formula (I) is orally administered.

19. The method of claim 15, wherein an aqueous suspension containing the compound of formula (I) is orally administered.

20. The method of claim 14, wherein the physiologically acceptable salt thereof is alkali metal, alkaline earth or ammonium salt.

21. The method of claim 14, wherein the effective amount is 200 to 1600 mg of the compound of formula (I).

22. The method of claim 14, wherein the disease characterized by a higher-than-normal level of dopaminergic activity in the basal ganglia comprises a disease characterized by a higher-than-normal level of dopaminergic activity in the human's striatum.

23. The method of claim 14, wherein the compound of formula (I) is administered in combination with an atypical antipsychotic drug.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc